For research use only. Not for therapeutic Use.
Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer[1].
Envonalkib (formula I) (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts[1].
| Catalog Number | I045110 |
| CAS Number | 1621519-26-3 |
| Synonyms | 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2S)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine |
| Molecular Formula | C24H26Cl2FN5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H26Cl2FN5O2/c1-13-10-29-6-7-32(13)21-9-19(33-3)16(12-30-21)15-8-20(24(28)31-11-15)34-14(2)22-17(25)4-5-18(27)23(22)26/h4-5,8-9,11-14,29H,6-7,10H2,1-3H3,(H2,28,31)/t13-,14+/m0/s1 |
| InChIKey | BVGDAZBTIVRTGO-UONOGXRCSA-N |
| SMILES | CC1CNCCN1C2=NC=C(C(=C2)OC)C3=CC(=C(N=C3)N)OC(C)C4=C(C=CC(=C4Cl)F)Cl |
| Reference | [1]. Feng G, et, al. Pyridine-substituted 2-aminopyridine protein kinase inhibitors. WO2016015676A1. |
